In:
Ophthalmic Research, S. Karger AG, Vol. 63, No. 5 ( 2020), p. 466-473
Abstract:
〈 b 〉 〈 i 〉 Purpose: 〈 /i 〉 〈 /b 〉 We investigated the characteristics, prognosis, and clinical outcome of the Charles Bonnet syndrome (CBS) in patients with neovascular age-related macular degeneration (AMD). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Five hundred psychiatrically healthy patients with neovascular AMD were screened for CBS. The individuals that fulfilled the inclusion criteria were systematically interviewed using a structured questionnaire that covered the impact, prognosis, risk factors, phenomenology, symptoms, and knowledge about the syndrome. A control group of 45 patients was used for comparison. Demographic data, current medication, and ocular risk factors were collected in all patients. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Forty-five patients with CBS were identified. The majority of patients reported images that consisted of colored (62%) animals (44%) or faces (42%) that lasted for seconds (53%). Most patients reported a self-limited disease with a median duration of symptoms between 9 and 11.5 months, with only 7% knowing about CBS at symptom onset. The degree of visual deficit did not predict the characteristics, complexity, frequency, duration, or impact of visual hallucinations. One-third of patients reported negative outcome, which was associated with shorter duration of CBS ( 〈 i 〉 p 〈 /i 〉 = 0.023), fear-inducing images ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), and impact on daily activities ( 〈 i 〉 p 〈 /i 〉 = 0.015). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 The prevalence of CBS in neovascular AMD patients is high and clinically relevant. Patients with recent onset of visual hallucinations and describing fear-inducing images are at greater risk for negative outcome. Periodic screening may minimize the negative consequences of this disease.
Type of Medium:
Online Resource
ISSN:
0030-3747
,
1423-0259
Language:
English
Publisher:
S. Karger AG
Publication Date:
2020
detail.hit.zdb_id:
1483177-6
Bookmarklink